Liminatus Pharma, Inc. (LIMN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Liminatus Pharma, Inc., an emerging growth company, on July 16, 2025. The report details a material definitive agreement entered into on the same date regarding the restructuring of equity instruments.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific capital transaction.
Material Changes and Transaction Details
On July 16, 2025, the Company entered into a Settlement and Release Agreement with Alta Partners, LLC. The key terms of this transaction are:
- Issuance: The Company agreed to issue 350,000 shares of Common Stock (par value $0.0001) to the Holder.
- Consideration: In exchange, the Holder surrendered and cancelled 1,000,000 warrants to purchase shares of Common Stock.
- Compensation: No commission or other remuneration was paid in connection with this exchange.
- Registration Status: The issuance of shares was unregistered, relying on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies beyond the standard disclosure of the unregistered sale of equity were detailed in this report.
Investor Verification Checklist
- Verify the impact of the 350,000 new shares on total outstanding share count and potential dilution.
- Confirm the cancellation of the 1,000,000 warrants and the removal of associated overhang.
- Review the full text of the Settlement and Release Agreement (Exhibit 10.1, if attached to the full filing) for any additional covenants or release terms.
- Check subsequent filings for any changes in the Company's capital structure or warrant exercise prices.